Webtherapy in morbid obesity, and these patients are frequently treated with warfarin despite the significant challenges in achieving therapeutic levels [8]. With the growing obesity epidemic, almost 40% of US adults are considered obese [9] and ∼7% are considered morbidly obese with a BMI⩾40 kg·m−2 [10]. Obesity is not only an independent ... WebNov 13, 2024 · Background: Obesity is a well-known risk factor for venous thromboembolism (VTE), however, obese patients are under-represented in clinical trials (1;2). Four direct oral anticoagulants (DOACs) have been approved for the treatment of acute VTE (3-6), including the direct Factor Xa inhibitors rivaroxaban, apixaban and …
Efficacy and Safety of DOACs in Morbidly Obese Patients
WebJul 1, 2024 · In conclusion, DOACs should be considered as an oral anticoagulant for preventing stroke or SE in morbidly obese patients with AF. A randomized controlled trial comparing a DOAC with warfarin is needed to confirm our meta-analysis results in morbidly obese patients with AF. Copyright © 2024 Elsevier Inc. All rights reserved. Publication … WebApr 13, 2024 · Based on eligibility criteria, the dataset of morbidly obese patients on DOACs was extracted from EHRs, pre-processed and analysed considering the access granted. After partitioning the entire dataset into a 70:30 split, the training dataset (70%) was run through selected machine learning (ML) classifiers (Random Forest, decision trees, K ... georgia state office of the registrar
Published Guidance - International Society on Thrombosis and ...
WebThe efficacy of DOACs over warfarin in obese patients with AF is less defined and may carry the potential for subtherapeutic anticoagulation and reduced efficacy. The best … WebJun 28, 2024 · This benefit was confirmed for patients with Class I and Class II obesity (body mass index [BMI] = 30.0-39.99 kg/m 2) based on post-hoc subgroup analysis. It is yet to be determined if direct oral anticoagulants (DOACs) are safe and efficacious for patients with Class III or morbid obesity (BMI ≥40kg/m 2 ). WebJul 19, 2024 · ISTH 2024: New guidelines on DOAC use in obese patients By Mardi Chapman 19 Jul 2024 New ISTH recommendations regarding the use of DOACs for VTE prevention suggest rivaroxoban or apixaban are among appropriate anticoagulant options regardless of high BMI or weight. georgia state office of registrar